Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue in Q2
Resolved · earnings · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-21. Check what remains unresolved below before relying on it.
Does the new outlook change what the company is worth?
Revenue mix shift toward newer therapies directly mitigates cash flow drag from upcoming patent expirations across BMY's $12.9B quarterly top line.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factBristol Myers Squibb reported Q2 revenue of $12.9 billion with 153% year-over-year EPS growth. |
| What else was confirmed? | Reported factThe company's growth portfolio of newer drugs expanded 15% year-over-year and now represents nearly 60% of total corporate revenue. |
| Does the valuation support acting? | Interpretation1 stored valuation assumptions for BMY; the latest is dated 2026-08-06. |
| What would change the assessment? | UnknownBMY Q3 Revenue Growth Mix — Quarterly earnings report verifying growth portfolio sustaining >=60% total revenue contribution. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Bristol Myers Squibb reported Q2 revenue of $12.9 billion with 153% year-over-year EPS growth.
- · The company's growth portfolio of newer drugs expanded 15% year-over-year and now represents nearly 60% of total corporate revenue.
- · BMY shares have risen 17% year-to-date while maintaining a valuation discount relative to large-cap pharmaceutical peers.
Public research record
Research framework · page evidenceCompleted event assessment
operating margin stabilization via growth drug commercialization
| Type | Claim | Scope |
|---|---|---|
| Assumption | Bristol Myers Squibb reported Q2 revenue of $12.9 billion with 153% year-over-year EPS growth. | 2026-09-21 |
| Interpretation | operating margin stabilization via growth drug commercialization | BMY |
Countercase, invalidators, and sources
Growth portfolio sales accelerate above 15% YoY, closing BMY's valuation gap versus biopharma peers.
- · BMY Q3 Revenue Growth Mix — Quarterly earnings report verifying growth portfolio sustaining >=60% total revenue contribution.
- Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder · 2026-09-20
What remains unresolved
- Base path
- Growth drug expansion continues to offset legacy drug declines, supporting stable cash generation.
- Adverse path
- Reimbursement friction or clinical headwinds slow growth portfolio adoption before legacy exclusivity expires.
- Supportive path
- Growth portfolio sales accelerate above 15% YoY, closing BMY's valuation gap versus biopharma peers.
- · BMY Q3 Revenue Growth Mix — Quarterly earnings report verifying growth portfolio sustaining >=60% total revenue contribution.next month
Evidence
- Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder2026-09-20
“Bristol Myers Squibb (BMY) is up 17% this year and trades at a discount to peers despite strong Q2 performance with $12.9B revenue and 153% EPS growth. The company's growth portfolio of newer drugs now accounts for nearly 60% of revenue and grew 15% year-over-year.”
Supports: BMY reported Q2 revenue of $12.9B, 153% EPS growth, and growth portfolio representing nearly 60% of revenue.